Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


 

E-learning: Quarterly Focus on Hemato-Oncology | Highlights in AML 2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Three high-impact, recent international publications on two main topics in AML will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The studio expert panel consists of: Prof. Gert Ossenkoppele, MD, PhD, hematologist, VUmc Amsterdam, The Netherlands Bas Wouters, MD, PhD, hematologist, ErasmusMC Rotterdam, The Netherlands Peter Valk, PhD, molecular biologist in hematology, ErasmusMC Rotterdam, The Netherlands Live video guests: Courtney Dinardo, MD, hemato-oncologist, MD Anderson Cancer Center, Houston, US Eytan Stein, MD, hemato-oncologist, MSKCC, New York, US Prof. Christian Thiede MD, PhD, professor in molecular hematology, Universitätsklinikum Dresden, Germany

  • 07 Jun 2018

Click here to select your areas of interest

Areas of interest

Select to filter on program types

Quarterly focus

E-learning: Quarterly Focus on Hemato-Oncology | Highlights in AML 2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Three high-impact, recent international publications on two main topics in AML will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The studio expert panel consists of: Prof. Gert Ossenkoppele, MD, PhD, hematologist, VUmc Amsterdam, The Netherlands Bas Wouters, MD, PhD, hematologist, ErasmusMC Rotterdam, The Netherlands Peter Valk, PhD, molecular biologist in hematology, ErasmusMC Rotterdam, The Netherlands Live video guests: Courtney Dinardo, MD, hemato-oncologist, MD Anderson Cancer Center, Houston, US Eytan Stein, MD, hemato-oncologist, MSKCC, New York, US Prof. Christian Thiede MD, PhD, professor in molecular hematology, Universitätsklinikum Dresden, Germany

Quarterly focus

September 25th: Quarterly Focus: highlights in Hodgkin Lymphoma

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. On September 25th, two high-impact international publications on Hodgkin Lymphoma of the past year will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The expert panel consists of: Josée Zijlstra, MD, PhD, hematologist, VUmc Amsterdam Wouter Plattel, MD, PhD, hematologist, UMC Groningen Live video guests: HD18: Prof. Peter Borchmann, MD, PhD, hematologist, University Hospital of Cologne, Germany H10: Prof. Massimo Federico, MD, PhD, medical oncologist, University of Modena and Reggio Emilia, Italy

Quarterly focus

Quarterly Focus on Hemato-Oncology | Highlights in AML

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not have always sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks.eu has developed a new program format, the 'Quarterly Focus, which brings together an expert panel and the authors of relevant, selected publications in an innovative way to explain and discuss the new data. The selection for the first edition of Quarterly Focus on Hemato-Oncology has been made by prof. dr. Gert Ossenkoppele, VUmc Amsterdam, Netherlands. Three pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the unique possibility to gain more insight into the selected publications and to interact with the expert panel and the authors. The expert panel consists of: Prof. Gert Ossenkoppele, MD, hematologist, VUmc, Amsterdam, Netherlands; Prof. Gerwin Huls, MD, hematologist, UMCG, Groningen; Netherlands; Peter Valk, Ph.D., molecular biologist, Erasmus MC, Rotterdam, Netherlands. Selected publications Quarterly Hemato-Oncology: Midostaurin plus chemotherapy for acute myeloid leukemia with FLT mutation N Engl J Med 2017 Prof. Richard Schlenk, MD, hematologist TP53 and decitabine in AML and myelodysplastic syndromes N Engl J Med 2016 Dr. John S. Welch, MD, Ph.D., hematologist Precision Oncology in acute myeloid leukemia using a knowledge bank approach. Nature Genetics, January 2017 Elli Papaemmanuil, Ph.D., molecular geneticist Accreditation: This program will be submitted for accreditation at the EBAH and Dutch NIV.

Congress news

Clinical updates from the EHA 2017 part 1

The 22nd European Hematology Association (EHA) took place in Madrid, Spain, on 22-25 June 2017. An international multidisciplinary panel discussed a selection of topics and new data on hematology during a live program. They gave an answer to what this newly acquired knowledge means for clinical practice. Topics New immunotherapy data for lymphoma The mechanisms behind iron overload New diagnostic markers for ITP Speakers Alicia Rovó, MD – hematologist, University Hospital of Bern, Bern, Switzerland Sigrid Machherndl-Spandl, MD – hematologist, Elisabethinen Hospital, Linz, Austria Moderator Prof. Harry Schouten, MD – hematologist, Maastricht UMC+, Maastricht, The Netherlands

Congress news

Clinical updates from the EHA 2017 part 2

The 22nd European Hematology Association (EHA) took place in Madrid, Spain, on 22-25 June 2017. An international multidisciplinary panel discussed a selection of topics and new data on hematology during a live program. They gave an answer to what this newly acquired knowledge means for clinical practice. Topics Immunotherapy for childhood ALL CML treatment in children and adults Treatment reduction in Hodgkin Lymphoma Fertility preservation The role of the microbiome to improve survival after allogeneic stem cell transplantation Prof. Harry Schouten, MD – hematologist, Maastricht UMC+, Maastricht, The Netherlands Speakers Thamer Sliwa, MD – hematologist, Hanusch Krankenhaus, Vienna, Austria Prof. Michel Zwaan, MD – pediatric hematologist, EMC, Rotterdam, The Netherlands Moderator Prof. Harry Schouten, MD – hematologist, Maastricht UMC+, Maastricht, The Netherlands

Congress news

EAHAD 2016: Highlight 1 – Von Willebrand Disease

Two original studies will be covered in the first highlight. In addition, the elements and usefulness of a VWD classification system are discussed. The presenting authors explain why it is important to restage VWD patients using current guidelines, and a controversial topic is breeched: can some VWD2B patients be treated with desmopressin prophylaxis before minor surgery, instead of FVIII concentrate, based on their genotype? Speakers: Carolyn Millar, MD, Hammersmith Hospital, London: The necessity of VWD subclassification Vuokko Jokela, MD, Helsinki University Central Hospital: Impact of platelet function on clinical phenotypes in Von Willebrand Disease: re-evaluation of 83 patient with historical diagnosis Lucia Rugeri, MD, Hôpital Cardiologique, Lyon: Genotyping might help therapeutic decision making in patients with Von Willebrand Disease type 2B (VWD2B)

Congress news

EAHAD 2016: Highlight 2 – Hemophilia A

This highlight is dedicated to hemophilia A. The latest updates of the SIPPET, FranceCoag en RODIN studies are presented and we cover original research. You will learn about PDI, a molecule that might (partly) explain variations in bleeding phenotypes. Also, the value of the TGA test is discussed. The highlight ends with a case discussion, which stresses the importance of a multidisciplinary approach and serves to explain the treatment of inhibitors with ITI. Speakers: Elena Santagostino, MD PhD, Maggiore Hospital Policlinico, Milan: TGA for testing of hemostatic effectiveness of fVIII concentrates in patients with Hemophilia A and inhibitors: in vitro results from the predicTGA study Prof. Cédric Hermans, MD, St-Luc University Hospital, Brussels: Updates on the SIPPET, FranceCoag and RODIN studies: the relationship between specific FVIII concentrate and inhibitor formation Katharina Holstein, MD, University Medical Centre, Hamburg: Expression and release of platelet protein disulfide isomerase (PDI) is increased in patients with hemophilia A Prof. Karin Fijnvandraat, MD, Academisch Medisch Centrum, Amsterdam: Case report - Multidisciplinary approach, treatment of inhibitors with ITI

Congress news

EAHAD 2016: Highlight 3 – Musculoskeletal complications

In highlight three, mobility takes the center stage. With hemophilia patient reaching advanced ages, is has become apparent that they have a higher chance of developing osteoporosis. The reasons and treatments of this complications will be explained to you. Other subjects include a new approach to treating inflammation during a joint bleed and joint outcomes in mild hemophilia patients. Speakers: Prof. Alok Srivastava, MD, Christian Medical College, Vellore: Low dose prophylaxis and treatment of joint inflammation caused by joint bleeds Mehdi Osooli, M.Sc., Lund University: Joint outcomes in mild hemophilia: a register based study Björn Rosengren, MD PhD, Skåne University Hospital, Malmö: Managing osteoporosis in hemophilia patients

Congress news

ISTH News | thrombosis: new developments

Round Table number 3 from the ISTH in Kyoto focuses on the status quo of the new oral anti-coagulants for the treatment of venous thromboembolism and prevention of recurrence as wel as for stroke prevention in patients with atrial fibrillation. Professor Gregory Lip and dr Menno Huisman summarize the current clinical data for the new oral anticoagulants for these indications and discuss the impact and challenges for daily clinical practice. Moderator of the Round Table is dr Evert-Jan de Kruijf, hematologist from the Netherlands.

Congress news

ASH 2014 Interview Dr. Saad Usmani

New developments in cytogenetic testing of Multiple Myeloma patients While multiple myeloma is an incurable disease, the prognosis of patients can vary greatly because of the genetic heterogeneity of the disease. The genetic profile of the malignant cells influences, amongst other things, the response to treatment. In this video, Dr. Saad Usmani will explain to us how the cytogenetic profile is currently determined and what the future will bring us. He will also discuss a new development in this field, the MMProfiler.

Congress news

ASH 2014 Highlight 1 - Multiple Myeloma

Highlight 1: multiple myeloma: Mark Sloan MD discusses induction regimens for transplant-eligible patients by comparing VTD with TD and VCD. Subsequently, Prof. dr. Torben Plesner elaborates on new data of the anti-CD-38 antibodies daratumumab and SAR650984. Prof. dr. Sonja Zweegman then illustrates the combined HOVON and NMSG phase III trial comparing MPT-T with MPR-R for transplant-ineligible patients. Lastly, Paul Richardson MD comments on the outcomes of the ASPIRE and STRATUS trials as new strategies for R/R disease.

Congress news

ASH 2014 Highlight 2 - Lymphoma

Highlight on lymphoma: First, Fredrick Hagemeister MD PhD discusses the usage of PD-1 targeted therapy in Hodgkin and Non-Hodgkin lymphoma. Christiane Pott MD PhD then illustrates the importance of minimal residual disease eradication in mantle cell lymphoma. Thereafter, Luca Biasco PhD and Serena Scala MSc explain how engineered T-cells can be employed to treat B-cell lymphomas. Finally, Jia Ruan MD PhD talks about new treatments for mantle cell lymphoma and specifically a chemotherapy-free regimen with the biologic doublet lenalidomide and rituximab.